Webinar: How EYRA and EYRAplex are qualified for multiplex immunogenicity assessment.
Testing for impurities: how EYRA and EYRAplex are qualified for multiplex immunogenicity assessment.
Join Mabtech and IQVIA Laboratories for this joint webinar to learn how EYRAplex has been qualified as a multiplex cytokine readout platform for immunogenicity‑relevant impurity testing.
Online
Trace impurities in biologic and peptide drugs can activate the innate immune system and lead to unwanted immunogenicity. Regulatory authorities are placing increased emphasis on impurity testing, making effective risk assessment more important than ever.
In this joint webinar, Mabtech and IQVIA Laboratories present how EYRAplex has been qualified as a multiplex cytokine analysis platform for the detection of innate immune response modulating impurities (IIRMI). The presentation will last approximately 45 minutes and will be followed by a live Q&A session. Participants are welcome to submit questions in advance or during the webinar.
Key topics include:
- The role of trace impurities in triggering innate immune responses
- Key considerations for IIRMI testing in biologics and peptide drugs
- How multiplex cytokine analysis supports immunogenicity assessment
- Qualification of EYRAplex for sensitive and reliable detection
- How EYRA and EYRAplex can support impurity testing workflows
Speaker
Berend Bassleer
MSc in Molecular Biology
Account Manager for Benelux and France at Mabtech since 2022; appointed Product Manager for Instruments in 2024.
Séverine Giltaire
PhD in Pharmaceutical and Biomedical Sciences
Senior Scientist and Team Lead of the Custom In Vitro Solutions department at IQVIA Laboratories
Sofie Denies
Master’s degree in Statistics and PhD in Immuno‑Oncology
Biostatistician at IQVIA Laboratories
Related images
